Upregulation of miRNA-200c during Disease Progression in COVID-19 Patients
Authors:
- Lukas van de SandLSLukas van de Sand
- Peer BraßPBPeer Braß
- Jonas GregoriusJGJonas Gregorius
- Kevin PattbergKevin Pattberg
- Andrea EnglerAEAndrea Engler
- Ulf DittmerUDUlf Dittmer
- Christian TaubeCTChristian Taube
- Stephan BrockSBStephan Brock
- Marc Moritz BergerMBMarc Moritz Berger
- Thorsten BrennerThorsten Brenner
- Oliver WitzkeOWOliver Witzke
- Adalbert KrawczykAdalbert Krawczyk
Open Access
- 29 December 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 283
Abstract
The COVID-19 pandemic has caused more than 6 million deaths worldwide since its first outbreak in December 2019 and continues to be a major health problem. Several studies have established that the infection by SARS-CoV-2 can be categorized in a viremic, acute and recovery or severe phase. Hyperinflammation during the acute pneumonia phase is a major cause of severe disease progression and death. Treatment of COVID-19 with directly acting antivirals is limited within a narrow window of time between first clinical symptoms and the hyperinflammatory response. Therefore, early initiation of treatment is crucial to assure optimal health care for patients. Molecular diagnostic biomarkers represent a potent tool to predict the course of disease and thus to assess the optimal treatment regimen and time point. Here, we investigated miRNA-200c as a potential marker for the prediction of the severity of COVID-19 to preventively initiate and personalize therapeutic interventions in the future. We found that miRNA-200c correlates with the severity of disease. With retrospective analysis, however, there is no correlation with prognosis at the time of hospitalization. Our study provides the basis for further evaluation of miRNA-200c as a predictive biomarker for the progress of COVID-19.Keywords
Funding Information
- Bundesministerium für Gesundheit (ZMI1-2521DAT20B)
- Stiftung Universitätsmedizin Essen (ZMI1-2521DAT20B)
- Rudolf Ackermann Foundation (ZMI1-2521DAT20B)
This publication has 49 references indexed in Scilit:
- MiR200c targets IRS1 and suppresses prostate cancer cell growthThe Prostate, 2015
- ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammationNature, 2012
- E‐cadherin transcriptional down‐regulation by epigenetic and microRNA‐200 family alterations is related to mesenchymal and drug‐resistant phenotypes in human breast cancer cellsInternational Journal of Cancer, 2010
- The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in miceExperimental Physiology, 2008
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- NF-κB regulation in the immune systemNature Reviews Immunology, 2002
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002
- Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related CarboxypeptidaseJournal of Biological Chemistry, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Influenza Virus-induced NF-κB-dependent Gene Expression Is Mediated by Overexpression of Viral Proteins and Involves Oxidative Radicals and Activation of IκB KinaseJournal of Biological Chemistry, 2000